Vanda Pharmaceuticals (VNDA) Phase III EPIONE study of tradipitant did not meet its primary endpoint
Go back to Vanda Pharmaceuticals (VNDA) Phase III EPIONE study of tradipitant did not meet its primary endpoint| Vanda Pharmaceuticals, Inc. (NASDAQ: VNDA) | Delayed: 6.00 +0.20 (3.45%) | |||||
|---|---|---|---|---|---|---|
| Previous Close | $5.80 | 52 Week High | $18.00 | |||
| Open | $5.86 | 52 Week Low | $6.91 | |||
| Day High | $6.06 | P/E | N/A | |||
| Day Low | $5.83 | EPS | $-0.67 | |||
| Volume | 879,392 | |||||
